Robert W. Baird Cuts Charles River Laboratories International (NYSE:CRL) Price Target to $270.00

Charles River Laboratories International (NYSE:CRL) had its price target dropped by Robert W. Baird from $282.00 to $270.00 in a research report issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price target would indicate a potential upside of 17.34% from the company’s current price.

Other research analysts have also issued research reports about the stock. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Evercore ISI boosted their target price on shares of Charles River Laboratories International from $260.00 to $265.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. increased their price target on Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. UBS Group boosted their price objective on Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, Citigroup raised their target price on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research note on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.38.

Charles River Laboratories International Price Performance

CRL stock opened at $230.11 on Friday. The company has a 50 day simple moving average of $250.70 and a 200 day simple moving average of $225.27. The stock has a market cap of $11.85 billion, a price-to-earnings ratio of 24.98, a P/E/G ratio of 1.83 and a beta of 1.44. Charles River Laboratories International has a 1 year low of $161.65 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.52 and a quick ratio of 1.16.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.05 by $0.22. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. Research analysts anticipate that Charles River Laboratories International will post 11.01 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In related news, EVP Victoria L. Creamer sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the transaction, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Charles River Laboratories International news, VP William D. Barbo sold 4,050 shares of the company’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $248.50, for a total value of $1,006,425.00. Following the transaction, the vice president now directly owns 22,879 shares in the company, valued at approximately $5,685,431.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the transaction, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The disclosure for this sale can be found here. Insiders sold 14,932 shares of company stock worth $3,693,663 over the last quarter. Corporate insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. VisionPoint Advisory Group LLC grew its holdings in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Charles River Laboratories International in the first quarter worth about $41,000. Operose Advisors LLC bought a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at about $42,000. Brown Brothers Harriman & Co. boosted its holdings in Charles River Laboratories International by 76.0% during the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 95 shares during the period. Finally, Sunbelt Securities Inc. grew its position in Charles River Laboratories International by 1,072.7% during the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock worth $70,000 after acquiring an additional 236 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).